
Progyny (PGNY) Stock Forecast & Price Target
Progyny (PGNY) Analyst Ratings
Bulls say
Progyny is expected to see continued growth in the fertility benefits market due to the implementation of California Senate Bill 729, its unique offerings and partnerships, and its focus on the fully-insured market. Additionally, the company's high-touch model and integration with health plans are expected to drive improved outcomes and cost savings, solidifying its market share and potential for further growth. Investors can expect Progyny to continue its strong performance and maintain its position as a leader in this growing niche market.
Bears say
Progyny is currently facing margin pressure due to increased investments in technology infrastructure, AI capabilities, and platform modernization, which has affected both operating expenses and capital expenditures. The company's membership growth may be sustainable, but renewal and expansion opportunities within the existing client base have historically varied. TrumpRx is seen as an unmanaged solution that may not cover all required medications for fertility treatment, potentially leading to uncertainty for patients. Additionally, while Progyny has experienced elevated free cash flow conversion, it may not be sustainable in the long term and the company has deliberately avoided owning a specialty pharmacy. The company's stock-based compensation expense is also expected to decline over time. Overall, the negative outlook is driven by concerns about the company's current margin pressure, potential difficulties in renewals and upsell opportunities, and uncertainty surrounding coverage for fertility treatments under TrumpRx.
This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares